Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central anxious technique, conolidine modulates alternate molecular targets. A Science Developments study observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://karelp001nak5.slypage.com/profile